Drug intelligence / Profile preview

TLM-006

Development stage: Unknown
Lead developer: TLM

Overview

TLM-006 is an investigational Therillume pipeline candidate for **glioblastoma multiforme**. Publicly available pipeline information identifies it only by the code name TLM-006 and places it in **Phase 1** development for GBM, with annotation that it has completed at least a **Phase Ib** clinical trial in this indication. No reliable public details were identified on its molecular target, modality, formulation, route, or mechanism of action, so it is best characterized as an early clinical-stage proprietary oncology asset from Therillume.

Beyond the preview

Go deeper on TLM-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLM-006.

Explore the full profile